Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Study of BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma Ended

2022-500687-35-00 Refractory Mantle Cell Lymphoma 9 2023-04-04
A First-In-Human Trial of the novel T cell Immunotherapy pTTL in Patients with Advanced Colorectal Cancer Ended

2024-512296-13-00 colorectal cancer 1 2023-04-03
PHASE 1/2A DOSE ESCALATION, FINDING AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR A… Ended

2024-515492-34-00 Breast Cancer, Ovarian Cancer, SCLC (Part 1 also had TN 9 2023-03-30
Sequential or up-front triple treatment with durvalumab, tremelimumab and bevacizumab for non-resectable hepatocellular carcinoma (HCC) pati… Ended

2024-511439-84-00 non-resectable hepatocellular carcinoma (HCC) 4 2023-03-30
Phase II study of Atezolizumab plus Tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal… Ended

2023-509485-38-00 Squamous cell carcinoma of the anal canal 4 2023-03-29
(Peak) A Clinical Study of CGT9486+Sunitinib vs Sunitinib in Patients with Gastrointestinal Stromal Tumors Ended

2022-500637-80-00 gastrointestinal stromal tumor 5 2023-03-28
A clinical trial to compare the effectiveness of savolitinib plus osimertinib versus chemotherapy for the treatment of non-small cell lung c… Ended

2024-511169-12-00 Non-Small Cell Lung Cancer 5 2023-03-28
Durvalumab (immunotherapy) maintenance after thoracic chemoradiotherapy (CRT) in frail small cell lung cancer patients whose disease is limi… Ended

2024-512224-11-00 Histologically confirmed frail Limited Disease Small Ce 4 2023-03-24
Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 … Ended

2023-507187-39-00 High-Risk Non-muscle-invasive Bladder Cancer 5 2023-03-23
A Phase 1b/2 Study of PF-07220060 in Combination with PF-07104091 Plus Endocrine Therapy in Participants with BC and other Advanced Solid Tu… Ended

2023-509504-15-00 HR-positive HER2-negative metastatic/advanced BC 4 2023-03-20
CAPTIRALL _ Combination of an Anti-PD1 antibody with CART cells Reinfusion in children, adolescents and young adults with Acute Lymphoblasti… Ended

2024-514345-11-00 children, adolescents and young adults with Acute Lymph 9 2023-03-15
A Study of Giredestrant in Patients with Grade 1 Endometrial Cancer Ended

2023-504091-23-00 Grade 1 Endometrial Cancer 4 2023-03-14
Phase 2 Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer Ended

2023-509583-22-00 Neoplasms, Rectal 4 2023-03-14
A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Un… Ended

2023-505211-21-00 Previously untreated locally advanced or metastatic non 4 2023-03-10
Phase I, open-label study to evaluate the safety and immune activity of PeptiCRAd-1, an oncolytic virus coated with tumor-specific peptides … Ended

2024-517580-23-00 Sarcoma 1 2023-03-07
An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult P… Ended

2024-510995-18-00 Advanced Solid Tumors 1 2023-03-01
A Clinical Study to evaluate the long-term safety of Daratumumab in combination with standard bone marrow cancer treatment regiments Ended

2022-500138-27-01 Multiple Myeloma 5 2023-02-28
An Open-Label Phase 1/2 Trial to Evaluate the Safety, Tolerability, and Efficacy of MORAb 202 in Subjects with Selected Tumor Types. Ended

2023-506868-14-00 Solid tumors in 4 tumor types: platinum resistant ovari 9 2023-02-28
A study of ONCOFID-P-B administered intravesically to patients with Carcinoma in Situ of the bladder who have not responded to the standard … Ended

2024-512568-72-00 BCG-unresponsive Carcinoma in Situ of the bladder with 5 2023-02-24
A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast C… Ended

2023-505552-22-00 Stage I-III Triple-negative Breast Cancer with residual 5 2023-02-24
A study evaluating the efficacy of axicabtagene ciloleucel versus standard of care therapy in patients with relapsed/refractory Follicular L… Ended

2024-511594-30-00 Relapsed/Refractory Follicular Lymphoma 5 2023-02-23
A phase II prospective, open-label, multi-centre, single arm study of sasanlimab plus sacituzumab govitecan in BCG (Bacillus Calmette-Guérin… Ended

2024-518486-10-00 Non-Muscle Invasive Bladder Cancer 4 2023-02-23
DARIUS : A randomized non-comparative phase II multicentric trial on short term DARolutamide (ODM-201) concomitant to radiation therapy for … Ended

2023-509494-23-00 Adult patients with intermediate unfavorable risk prost 4 2023-02-20
An open-label, single-arm, Phase II, multinational, multicentre study to assess the efficacy and safety of 5 years of osimertinib in partici… Ended

2023-508740-21-00 Non-Small Cell Lung Cancer 4 2023-02-15